HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
OTC Drugs

Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J

This article was originally published in The Tan Sheet

  • News

Executive Summary

Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings

You may also be interested in...



Top Stories Of 2007: From Talk Of BTC To Supplement GMPs

The past year offered anticipated changes and moves as well as some unexpected thrills and chills for the nonprescription drugs and nutritional products industries

Zyrtec-D Switch Approved – J&J Will Launch Behind The Counter This Year

FDA approved Johnson & Johnson's bid to switch prescription antihistamine/nasal decongestant Zyrtec-D to nonprescription status, but the firm is still awaiting a reply on single-ingredient Zyrtec

J&J Consumer Rides International Sales Growth Gained In Pfizer Acquisition

Last year's acquisition of Pfizer's Consumer Healthcare unit drove Johnson & Johnson's consumer products segment revenue and increased the proportion of international sales in OTCs and nutritionals
Table

View full table

Related Content

Pink Sheet Pink Sheet Pink Sheet Pink Sheet

Topics

Tags:
OTC Drugs
UsernamePublicRestriction

Register

RS138345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By